Genmab A/S
(WBO:GMAB)
€
246
1 (0.41%)
Market Cap: 15.78 Bil
Enterprise Value: 11.95 Bil
PE Ratio: 22.12
PB Ratio: 3.67
GF Score: 90/100 
Q1 2024 Genmab A/S Earnings Call TranscriptMay 02, 2024€259.4 (-1.33%)Earnings- Genmab A/S Annual Shareholders Meeting TranscriptMar 13, 2024
- Q4 2023 Genmab A/S Earnings Call TranscriptFeb 14, 2024€257.2 (+3.54%)Earnings
- Genmab A/S at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Genmab A/S R&D Update and ASH Data Review TranscriptDec 12, 2023
- Q3 2023 Genmab A/S Earnings Call TranscriptNov 07, 2023€276.1 (+3.02%)Earnings
- Genmab A/S at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Half Year 2023 Genmab A/S Earnings Call TranscriptAug 03, 2023€353.9 (-1.72%)Earnings
- Genmab A/S at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Q1 2023 Genmab A/S Earnings Call TranscriptMay 10, 2023€361.7 (-0.17%)Earnings
- Genmab A/S Annual Shareholders Meeting TranscriptMar 29, 2023
- Q4 2022 Genmab A/S Earnings Call TranscriptFeb 22, 2023€371.1Earnings
- Genmab A/S at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Genmab A/S R&D Update and ASH Data Review TranscriptDec 13, 2022
- Q3 2022 Genmab A/S Earnings Call TranscriptNov 09, 2022€396Earnings
- Genmab A/S at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- Q2 2022 Genmab A/S Earnings Call TranscriptAug 10, 2022€346.1 (+0.32%)Earnings
- Genmab A/S at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- Q1 2022 Genmab A/S Earnings Call TranscriptMay 11, 2022€275.2 (-1.50%)Earnings
- Genmab A/S Annual Shareholders Meeting TranscriptMar 29, 2022
- Q4 2021 Genmab A/S Earnings Call TranscriptFeb 16, 2022€299.1 (+0.17%)Earnings
- Genmab A/S at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2022
- Genmab A/S Virtual R&D Update and ASH Data Review TranscriptDec 14, 2021
- Q3 2021 Genmab A/S Earnings Call TranscriptNov 10, 2021€375 (-4.07%)Earnings
- Genmab A/S at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 09, 2021
- Q2 2021 Genmab A/S Earnings Call TranscriptAug 11, 2021€381.5 (-1.42%)Earnings
- Genmab A/S at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- Q1 2021 Genmab A/S Earnings Call TranscriptMay 05, 2021€300.2 (+0.67%)Earnings
- Genmab A/S Annual Shareholders Meeting TranscriptApr 13, 2021
- Q4 2020 Genmab A/S Earnings Call TranscriptFeb 23, 2021€299.1 (-5.41%)Earnings
- Genmab A/S at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Genmab A/S Virtual 2020 ASH Data Review Meeting TranscriptDec 08, 2020
- Genmab A/S Virtual Capital Markets Day TranscriptNov 13, 2020
- Q3 2020 Genmab A/S Earnings Call TranscriptNov 04, 2020€318.1 (+8.90%)Earnings
- Genmab A/S at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2020
- Q2 2020 Genmab A/S Earnings Call TranscriptAug 12, 2020Earnings
- Genmab A/S at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Genmab A/S to Discuss Broad Oncology Collaboration with Abbvie Inc Call TranscriptJun 10, 2020
- Q1 2020 Genmab A/S Earnings Call TranscriptMay 06, 2020Earnings
- Genmab A/S Annual Shareholders Meeting TranscriptMar 26, 2020
- Genmab A/S at PR Newswire and BetterInvesting (NAIC) Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptMar 18, 2020
- Q4 2019 Genmab A/S Earnings Call TranscriptFeb 19, 2020Earnings
- Genmab A/S at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Genmab A/S 2019 R&D Update and ASH Data Review Meeting TranscriptDec 10, 2019
- Q3 2019 Genmab A/S Earnings Call TranscriptNov 06, 2019Earnings
- Q2 2019 Genmab A/S Earnings Call TranscriptAug 14, 2019Earnings
- Q1 2019 Genmab A/S Earnings Call TranscriptMay 08, 2019Earnings
- Q4 2018 Genmab A/S Earnings Call TranscriptFeb 20, 2019Earnings
Genmab A/S Annual Shareholders Meeting Transcript
Mar 26, 2020 / 01:00PM GMT
JÃ;rgen Kjergaard Madsen
Kromann Reumert - Chairman of the Board of Directors and Partner
¸ -
[Interpreted] Good afternoon. I'm Jorgen Kjergaard Madsen. I am the Genmab's External Legal Adviser, member of -- a partner of Kromann Reumert. And I have been appointed as Chairman of this Annual General Meeting. Before we open the Annual General Meeting, I'd like to comment on the special circumstances that are relevant for today's meeting.
Genmab has been keeping a keen eye on the development and the spread of COVID-19. And as a preventive measure and on the basis of recent guidance from Danish authorities, and in the interest of shareholders, management and staff, we have decided to minimize the physical presence of this meeting, and it is more or less virtual Annual General Meeting. We are live screening. And this means we comply with the social distancing rules and the restriction on numbers in a single room. This means also that there will be no service of food because we are trying to minimize problems.
This, of course, does not benefit the development and the compliance
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers